Several other research firms have also commented on AMGN. Jefferies Group reissued a buy rating and issued a $198.00 target price on shares of Amgen in a report on Tuesday, August 23rd. Vetr upgraded shares of Amgen from a sell rating to a hold rating and set a $171.34 price objective for the company in a research note on Wednesday, August 3rd. Leerink Swann restated a hold rating on shares of Amgen in a research note on Saturday, September 17th. Credit Suisse Group AG set a $206.00 price objective on shares of Amgen and gave the company a buy rating in a research note on Saturday, September 17th. Finally, Argus restated a buy rating and issued a $195.00 price objective (up previously from $185.00) on shares of Amgen in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. Amgen presently has an average rating of Buy and a consensus price target of $184.56.
Amgen (NASDAQ:AMGN) opened at 175.62 on Monday. The stock has a market cap of $131.43 billion, a price-to-earnings ratio of 17.97 and a beta of 0.87. The company has a 50 day moving average price of $172.03 and a 200 day moving average price of $159.88. Amgen has a 52 week low of $130.09 and a 52 week high of $176.64.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.74 by $0.10. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. Amgen’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.57 earnings per share. Analysts expect that Amgen will post $11.36 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were given a dividend of $1.00 per share. The ex-dividend date was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a yield of 2.28%. Amgen’s dividend payout ratio (DPR) is currently 40.90%.
In related news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Fulton Bank N.A. raised its position in shares of Amgen by 189.5% in the first quarter. Fulton Bank N.A. now owns 10,834 shares of the medical research company’s stock worth $1,624,000 after buying an additional 7,092 shares during the period. Abner Herrman & Brock LLC raised its position in shares of Amgen by 430.9% in the first quarter. Abner Herrman & Brock LLC now owns 31,136 shares of the medical research company’s stock worth $4,668,000 after buying an additional 25,271 shares during the period. CHICAGO TRUST Co NA raised its position in shares of Amgen by 3.6% in the first quarter. CHICAGO TRUST Co NA now owns 16,902 shares of the medical research company’s stock worth $2,534,000 after buying an additional 590 shares during the period. DnB Asset Management AS raised its position in shares of Amgen by 69.2% in the first quarter. DnB Asset Management AS now owns 62,366 shares of the medical research company’s stock worth $9,351,000 after buying an additional 25,500 shares during the period. Finally, CENTRAL TRUST Co bought a new position in shares of Amgen during the first quarter worth $7,309,000. Institutional investors own 79.15% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.